A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer
Keyword(s):
Phase 2
◽
2018 ◽
Vol 36
(15_suppl)
◽
pp. 3557-3557
◽